Related Experiment Video
Updated: May 4, 2026

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model
Published on: November 4, 2022
GI-4000 in KRAS mutant cancers
1Indiana University School of Medicine, Department of Medicine , 535 Barnhill Dr RT 473, Indianapolis, IN 46202 , USA shahdas@iu.edu.
Introduction:
Cancer develops mainly as a result of accumulating mutations in genes controlling cell growth regulation. RAS is one of the most commonly mutated genes in cancer. While agents targeting the signaling aspects of RAS have met with some success, resistance to therapy remains a major issue. Another focus of drug development has been to harness the immune system to target cells harboring mutated proteins, which can appear 'foreign' to the immune system. It has been observed that cancer is able to avoid regular immune surveillance through local and systemic mechanisms leading to immune tolerance. One potential way of breaking immune tolerance is through vaccine therapy.
Areas Covered:
The authors review the current but limited available literature on KRAS vaccine therapy. The research reviewed was identified from PubMed and presentations from national oncology meetings related to KRAS vaccines in general and GI-4000 series specifically.
Expert Opinion:
While targeting KRAS has proven difficulties, developing novel vaccine approaches such as 'tarmogens' appear to be safe with early efficacy in subset of patients with KRAS mutations. However, further research is crucial to identify this group of patients and develop biomarkers.
Insights
Novel cancer vaccines targeting KRAS mutations show early promise. While challenges remain, these new approaches, including tarmogens, are safe and effective in some patients, necessitating further research for biomarker identification.
Area of Science:
- Oncology
- Immunotherapy
- Cancer Genetics
Background:
- Cancer arises from mutations in cell growth regulatory genes, with RAS being frequently altered.
- Targeting RAS signaling has limitations due to therapeutic resistance.
- Harnessing the immune system against mutated proteins offers an alternative therapeutic strategy.
Purpose of the Study:
- To review the current literature on KRAS vaccine therapy.
- To explore novel approaches for overcoming immune tolerance in cancer.
Main Methods:
- Literature review of KRAS vaccine therapy.
- Inclusion of studies identified from PubMed and national oncology meeting presentations.
- Focus on KRAS vaccines, including the GI-4000 series.
Main Results:
- KRAS targeting presents therapeutic challenges.
- Novel vaccine strategies, such as tarmogens, demonstrate safety.
- Early efficacy observed in a subset of patients with KRAS mutations.
Conclusions:
- Tarmogen vaccines are a promising avenue for KRAS-mutated cancers.
- Identifying patient subsets and developing biomarkers are critical for optimizing vaccine therapy.
- Further research is essential to advance KRAS vaccine development.
Related Concept Videos
The Ras Gene
Ras is a...
In-vitro Mutagenesis
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...

